2. 2
TABLE OF CONTENTS
(BY SECTION)
About us
Who we are
▪ Founding
▪ Our Mission
▪ Innovation timeline
What we do
▪ Addressing, transforming
▪ Our therapies and solutions
▪ Our business groups
▪ Technology innovation
How we do it
▪ Our people, workplace, & global presence
▪ Culture of quality
▪ Commitment to the community
Appendix
▪ Our leaders
1
2
3
4
5
4. 4
Company Presentation | July 2019
MEDICAL TECHNOLOGY
IS WHAT WE DO.
IT’S WHAT WE’VE
ALWAYS DONE.
You may know us as the pacemaker company,
the diabetes pump maker, or
deep-brain stimulation experts —
and we do so much more.
5. Therapies to treat more than
70 conditions in the human body
Abdominal Aortic Aneurysm (AAA) • Atrial Fibrillation • Barrett’s Esophagus • Blood Pressure Basics • Bradycardia (Slow
Heartbeat) • Breath Monitoring • Cancer Pain • Cervical Herniated Discs • Cervical Disc Degeneration • Chronic Pain • Colon
Disease • Coronary Artery Disease (CAD) • Crohn’s Disease • Dysphagia (Difficulty Swallowing) • Dystonia • Ear Infections •
Epilepsy • Essential Tremor • Fecal Incontinence • Gastroesophageal Reflux Disease (GERD) • Gastroparesis • GI Bleeding •
Hearing Loss • Heart Failure • Heart Palpitations • Heart Valve Disease • Hernia • Hydrocephalus • Idiopathic Intracranial
Hypertension • Lung Cancer • Normal Pressure Hydrocephalus • Obesity • Obsessive-Compulsive Disorder (OCD) • Overactive
Bladder • Parkinson’s Disease • Peripheral Arterial Disease • Polyps • Pulmonary Valve Disease • Sacroiliac Joint Dysfunction •
Scoliosis • Severe Spasticity • Sinus Infections • Spinal Fractures • Suspected Atrial Fibrillation • Tachycardia (Fast Heartbeat) •
Thoracic Aortic Aneurysm (TAA) • Thyroid Conditions • Type 1 & Type 2 Diabetes • Unexplained Fainting • Unexplained Stroke •
Urinary Retention
5
Company Presentation | July 2019
WE CREATE
INNOVATIONS
AT THE
THERAPEUTIC,
PROCEDURAL,
AND SYSTEM LEVEL
6. Ablation products • Aortic stent graft products • Balloon kyphoplasty • Biomaterials • Bone conductive hearing device • Brain monitoring •
Capnography monitoring • Cardiac monitors • Cardiac resynchronization therapy (CRT) systems • Cardiopulmonary products •
Cerebral/somatic oximetry • Continuous Glucose Monitoring system • Coronary stents • Cranial repair products • Deep brain stimulation
system • Dialysis • Drug-coated balloons • Drug infusion systems • Electrosurgical products • Endoscopic ultrasound products • External
defibrillators • Gastric electrical stimulation systems • Health informatics & monitoring • Heart valves replacement • Hernia repair • High-
speed surgical drills & tools • Hysteroscopy systems • Image-guided surgery • Implantable cardiac defibrillator (ICD) systems • Infusion sets
• Insulin pumps with continuous monitors • Laser ablation technology • Motility testing products • Nerve monitoring products • Pacing
systems • Peripheral embolization products • Reflux testing products • Revascularization products • Sacral neuromodulation systems •
Shunts • Smoke evacuation systems • Spine robotics • Support catheters • Surgical navigation systems • Surgical stapling • Therapy
management software • Tumor management • Ultrasonic dissection • Ventricular assist devices (VAD) • Vertebroplasty • Vessel sealing •
Wound closure
6
Company Presentation | July 2019
WE CREATE
INNOVATIONS
AT THE
THERAPEUTIC,
PROCEDURAL,
AND SYSTEM LEVEL
More than 49,000+ patents in our total portfolio
9. 9
THE PANDEMIC BECAME A CATALYST FOR CHANGE
We are innovating in new ways and partnering with
new companies to help aid the pandemic relief efforts
through work such as:
▪ The development of personal protective equipment using 3-D scanners
▪ The creation of a new, simple, low-cost ventilator made in partnership
with the University of Minnesota, Boston Scientific, UnitedHealth Group
and others, and more
CARING FOR COMMUNITIES
The Medtronic Foundation found
ways to amplify our employees’
passion to help through:
$13M
2:1* *2:1 matching from June– March 2020
COMMITMENT TO COVID-19
RESPONSE EFFORTS
DONATION
MATCHING
10. 10
THE PANDEMIC BECAME A CATALYST FOR CHANGE
We are working with others to increase the global supply
of ventilators by:
▪ Increasing our production of ventilators
▪ Publicly sharing the design specifications for our portable compact
ventilator to allow others around the world to join the fight
Within the first week
of open sourcing the design specs
of our portable compact ventilator
90,000 people registered
for the download
11. 11
THE PANDEMIC BECAME A CATALYST FOR CHANGE
We are finding new ways to safely serve patients, by:
▪ Using existing remote patient monitoring devices in new ways
▪ Developing remote management capabilities for our most advanced
ventilator to help reduce healthcare worker exposure
12. To learn more about our efforts, visit:
www.medtronic.com/covid19
THE ROAD TO RECOVERY
12
15. 15
Company Presentation | July 2019
FOUNDED ON
INNOVATION AND
COLLABORATION
Since the late 1940s, we have been
working with others to
alleviate pain, restore health, and extend life.
Our late co-founder and
lifelong innovator, Earl
Bakken, holding the
world’s smallest
pacemaker today next to
the world’s first
pacemaker (1957), both
developed by Medtronic.
16. WRITTEN IN 1960, OUR MISSION
DRIVES EVERYTHING WE DO.
To contribute to human welfare by application of
biomedical engineering in the research, design,
manufacture, and sale of instruments or appliances
that alleviate pain, restore health, and extend life.
1
To direct our growth in the areas of biomedical engineering.
2
To strive without reserve for the greatest possible
reliability and quality in our products.
3
To make a fair profit.
4
To recognize the personal worth of all employees.
5
To maintain good citizenship.
6
16
17. OUR RICH HISTORY OF INNOVATION
HOW WE’VE GROWN OVER THE YEARS
1960
1949 1977
1983
1999
2001
2002
2015
2017
MEDTRONIC
IS FOUNDED
1957
1979
CREATED FIRST
BATTERY-
OPERATED,
EXTERNAL
PACEMAKER
EXPANDED
INTO
NEURO-
STIMULATION
INTRODUCED
PROSTHETIC
HEART VALVE
EXPANDED
INTO
SPINAL
CARE
INTRODUCED
FIRST REMOTE
MONITORING
SYSTEM
ACQUIRED
COVIDIEN
EXPANDED
INTO
DIABETES
CARE ESTABLISHED
THE
MEDTRONIC
FOUNDATION
WROTE
OUR
MISSION
INTRODUCED
THE WORLD’S SMALLEST
PACEMAKER
AND THE
FIRST HYBRID
CLOSED LOOP INSULIN
DELIVERY SYSTEM
2016
INTRODUCED
THE WORLD'S
SMALLEST
IMPLANTABLE
SPINAL CORD
STIMULATOR
17
DEVELOPED
THE FIRST
IMPLANTABLE
PACEMAKER
2019
LAUNCHED
MAZOR X STEALTH
EDITIONSYSTEM
FOR ROBOTIC-
ASSISTED SPINE
SURGERY
18. TWO-COLUMN CONTENT SLIDE
MEDICAL
TECHNOLOGY
HAS THE
POWER TO
CHANGE LIVES
We believe technology is part of the
solution to making healthcare better —
technology in devices, in processes,
and in healthcare systems around
the world.
19. “The future of healthcare requires new
approaches and new forms of
innovation. Medtronic is stepping
forward to put the full power of our
technologies — and our people — to
work with new partners, in new ways,
and drive value across the healthcare
ecosystem. Only through collaboration
can we drive healthcare toward a
healthier, more efficient future.
— Medtronic Chief Executive Officer, Geoff Martha
“
“
21. ADDRESS UNIVERSAL
HEALTHCARE CHALLENGES
Populations are aging Chronic diseases are rising Many payment and
delivery systems reward
volume over value
Government policies and
regulatory systems are
impacting innovations and
increasing time to market
21
Company Presentation | July 2019
22. 22
Company Presentation | July 2019
COMMITTED TO HELPING
TRANSFORM HEALTHCARE
GLOBALIZATION
THERAPY
INNOVATION
Introducing and
delivering meaningful
offerings at the
therapeutic, procedural,
and system level
Addressing the
inequities in healthcare
access globally
ECONOMIC
VALUE
Helping lead the creation
of value-based
healthcare solutions
23. 23
Company Presentation | July 2019
OUR THERAPIES AND
SOLUTIONS IMPROVE LIVES
More than 70 conditions in
the human body are treated
with our therapies, enabling
us to address chronic
conditions and provide
healthcare solutions
BRAIN
EAR, NOSE & THROAT
HEART & VASCULAR
AIRWAY & LUNG
SPINE & ORTHOPEDIC
DIABETES
DIGESTIVE,
GASTROINTESTINAL,
UROGYNECOLOGICAL,
& UROLOGICAL
PAIN
24. 24
WE OFFER THERAPIES AND SOLUTIONS
ACROSS OUR FOUR BUSINESS GROUPS
Company Presentation | July 2019
CARDIAC &
VASCULAR
GROUP
▪ Aortic, Peripheral and Venous
▪ Cardiac Ablation Solutions
▪ Cardiac Rhythm and Heart
Failure
▪ Coronary and Structural Heart
DIABETES
GROUP
Therapies and services for insulin
dependent Type 1 and Type 2
patients
MINIMALLY
INVASIVE
THERAPIES
GROUP
▪ Renal Care Solutions
▪ Respiratory, Gastrointestinal
and Informatics
▪ Surgical Innovations
RESTORATIVE
THERAPIES
GROUP
▪ Cranial and Spinal Technologies
▪ Neuromodulation
▪ Specialty Therapies
25. 25
Company Presentation | July 2019
▪ Aortic, Peripheral and Venous
▪ Cardiac Ablation Solutions
▪ Cardiac Rhythm and Heart Failure
▪ Coronary and Structural Heart
CARDIAC &
VASCULAR
GROUP
Cardiac Cryoballoon
Catheter
Transcatheter
Heart Valves
Transcatheter
Pacing System
Thoracic Stent
Graft System
26. 26
Company Presentation | July 2019
Therapies and services for insulin dependent
Type 1 and Type 2 patients
DIABETES
GROUP
Mobile
Monitoring
Tools
Diagnostic CGM
Insulin Pumps with
built-in Continuous
Glucose Monitoring
27. 27
Company Presentation | July 2019
▪ Renal Care Solutions
▪ Respiratory, Gastrointestinal
and Informatics
▪ Surgical Innovations
MINIMALLY
INVASIVE
THERAPIES
GROUP
Navigation
Systems
Tri-stapling Systems
Capnography
28. 28
Company Presentation | July 2019
▪ Cranial and Spinal Technologies
▪ Neuromodulation
▪ Specialty Therapies
RESTORATIVE
THERAPIES
GROUP
Targeted Drug Delivery
Revascularization
Devices
Spine
Systems
29. 29
Company Presentation | July 2019
MEDTRONIC CONTINUES TO LEAD
IN TECHNOLOGY INNOVATION
Reveal LINQ™ ICM
CoreValve™
TAVR
Solitaire™
Revascularization
PillCam™ Capsule
Endoscopy
Surgical Robotics
System
Arctic Front Advance™
Cryoballoon
MiniMed™ 670G
Insulin Pump System
Micra™ Wireless
Pacing System
Continuous Innovation
Enhancing the clinical outcomes and
economic value of existing products
Invention
creating and developing new therapies
that result in new markets
Disruption
Disruptive therapies in existing markets
StealthStation™
Surgical Navigation
Resolute ONYX™
Drug-eluting stent
VisiaAF™ ICD Signia™ Surgical
Stapling
Intellis™ Implantable
Neurostimulator
Azure™ Pacing
System
*Pipeline — Product concept in development
31. 31
Company Presentation | July 2019
OUR PEOPLE
Medtronic employee Amanda Miranda returned to work as a
biomedical engineer after spending six years away to attend to
her family. Through Careers 2.0 — a Medtronic hiring initiative
for women in engineeringthat helps them return to the industry
after personal time away — Miranda found a position that fits her
skills and helps her feel like she’s making a difference.
90,000+
EMPLOYEES
And tremendous
clinical expertise
and investments*:
* Numbers are representative of this past year.
10,700+
SCIENTISTS
& ENGINEERS
1,700+
CLINICAL
PROFESSIONALS
▪ $2.3 billion in R&D investments
▪ $465+ million in clinical investments
▪ 4,400+ patents
▪ 350+ clinical trials
Expertise to achieve our Mission
32. 32
OUR WORKPLACE
Company Presentation | July 2019
Corporate
Responsibility
Magazine
recognizes
Medtronic on
100 Best
Corporate
Citizens List
Wall Street
Journal
recognizes
Medtronic as
a “Best Run
Company”
in 2019
DiversityInc
Recognizes
Medtronic
in Annual
“Top 50” list for
the fourth year
in a row
Catalyst
recognizes
Medtronic as an
organization
that advances
women in
leadership roles
Forbes
Magazine
named
Medtronic
one of
“America’s Best
Employers For
New Grads”
Fortune
Magazine
recognizes
Medtronic as a
diverse and
inclusive
company
Attracting and recognizing the best talent
33. 33
Company Presentation | July 2019
OUR GLOBAL PRESENCE
Headquarter Locations
Medtronic Operational Headquarters
Minneapolis, Minnesota
Medtronic Principal Executive Office
Dublin, Ireland
AMERICAS
EUROPE, MIDDLE EAST, & AFRICA
ASIA PACIFIC
GREATER CHINA
REGIONS
4
ORGANIZED IN
DISTRIBUTION
SITES
19 MANUFACTURING
SITES
74
COUNTRIES
150+
OPERATE IN
Helping more people in more places
34. 34
Company Presentation | July 2019
OUR COMMITMENT TO QUALITY
IS ROOTED IN PATIENT SAFETY
Ensuring reliable, effective, and safe products
Quality and reliability are the
DNA of our company, making
them cornerstones of the
Mission statement.
It informs the Medtronic business
strategy in therapy innovation,
globalization, and economic value,
and guides global teams when
they interact with customers,
collaborators, regulators, and
one another.
35. 35
DRIVING A MINDSET OF EXCELLENCE
THROUGH A CULTURE OF QUALITY
Company Presentation | July 2019
FIVE BENEFITS OF
A CULTURE OF QUALITY
1. Greater patient health and safety
2. Accountable and empowered employees
3. Heightened credibility with partners
4. Innovative culture
5. Stronger cost efficiencies
“Building a culture of quality is the
greatest commitment we can make to
our customers, clinicians, and patients,”
says Omar Ishrak, Medtronic Chairman &
Chairman of the Board
36. 36
OUR COMMITMENT TO THE COMMUNITY
FY20 Company Presentation | July 2019
33%
MEDTRONIC
FOUNDATION
GIVING ($34.2M)
54%
CASH
CONTRIBUTIONS
($56.4M)
10%
PRODUCT
DONATIONS ($10.2M)
4%
EMPLOYEE
VOLUNTEERISM
($4.3M)
$105
TOTAL:
MILLION
Philanthropic giving and volunteerism
37. 37
FY20 Company Presentation | July 2019
Through progress and partnership we are reaching further than ever before to transform
healthcare. This means helping our partners and providers improve quality and efficiency
of care through medical technology and deep clinical expertise.
PROGRESS PARTNERSHIP
40. 40
FY20 Company Presentation | July 2019
OUR LEADERS
Shaping healthcare’s future
CHRIS
LEE
SVP and President,
Asia Pacific Region
RICHARD E.
KUNTZ, MD, MSC
SVP and Chief Medical
and Scientific Officer
GEOFFREY S.
MARTHA
Chief Executive
Officer
OMAR
ISHRAK
Executive Chairman
and Chairman of
the Board
NOEL
COLÓN
SVP and Chief
Quality Officer
JOHN
LIDDICOAT, MD
EVP and President,
Americas Region
MICHAEL J.
COYLE
EVP and President,
Cardiac and
VascularGroup
ALEX
GU
SVP and President,
Greater China
BRAD
LERMAN
SVP, General Counsel
and Corporate
Secretary
KAREN L.
PARKHILL
EVP and Chief
Financial Officer
SEAN
SALMON
EVP and President,
Diabetes Group
ROB
TEN HOEDT
EVP and President,
Europe, Middle East,
and Africa Region
BRETT
WALL
EVP and President,
Restorative
Therapies Group
CAROL A.
SURFACE, PHD
SVP and Chief Human
Resources Officer
BOB
WHITE
EVP and President,
Minimally Invasive
Therapies Group
MIKE
WEINSTEIN
SVP, Strategy
LAURA MAURI,
MD, MSC
SVP and Chief Clinical
& Regulatory Officer
